Company: LCTX
Filing Date: 2025-11-12
Form Type: 8-K
Source: 0001193125-25-276249
Chunk: 0

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-11-12
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01 Other Events.

On November 12, 2025, Lineage Cell Therapeutics, Inc. (the “ Company”) sold 12,000,000 common shares to Janus Henderson Investors at a purchase price of $1.75 per share in a block transaction under its at-the-market offering program. The Company received $21 million in gross proceeds, before deducting fees and other expenses payable by it.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                                                Lineage Cell Therapeutics, Inc.          
  Date:      November 12, 2025      By:         /s/ George A. Samuel III                 
                                    Name:       George A. Samuel III